Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

ESMO 2020

18 - 22 Sep 2020
Online, Global
OS results from SOLAR-1: Alpelisib plus fulvestrant for HR positive, HER2 negati...
Prof Fabrice André - Institut Gustave Roussy, Paris, France
OS results from SOLAR-1: Alpelisib plus fulvestrant for HR positive, HER2 negative advanced breast cancer ( Prof Fabrice André - Institut Gustave Roussy, Paris, France )
29 Sep 2020
ESMO 2020 melanoma roundup
Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany
ESMO 2020 melanoma roundup ( Dr Teresa Amaral - University Hospital Tübingen, Tübingen, Germany )
28 Sep 2020
Nivolumab for oesophageal cancer following chemoradiation therapy
Dr Ronan Kelly - Charles A. Sammons Cancer Center, Dallas, USA
Nivolumab for oesophageal cancer following chemoradiation therapy ( Dr Ronan Kelly - Charles A. Sammons Cancer Center, Dallas, USA )
25 Sep 2020
PROFound trial and other recent updates in prostate cancer
Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain
PROFound trial and other recent updates in prostate cancer ( Dr Joaquin Mateo - Vall d'Hebron Institute of Oncology, Barcelona, Spain )
25 Sep 2020
ESMO 2020 renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2020 renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
25 Sep 2020
Exon 20 insertions in NSCLC - ESMO 2020
Dr Alex Spira, Prof Benjamin Besse, Prof Michael Thomas and Dr Antonio Passaro
Exon 20 insertions in NSCLC - ESMO 2020 ( Dr Alex Spira, Prof Benjamin Besse, Prof Michael Thomas and Dr Antonio Passaro )
25 Sep 2020
ESMO 2020: Lung cancer latest
Prof Solange Peters, Dr Federico Cappuzzo, Dr Antonio Passaro and Prof Sanjay Po...
ESMO 2020: Lung cancer latest ( Prof Solange Peters, Dr Federico Cappuzzo, Dr Antonio Passaro and Prof Sanjay Popat )
25 Sep 2020
Highlights from ESMO 2020
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Highlights from ESMO 2020 ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
25 Sep 2020
Latest in bladder cancer with FGFR 2 and 3 mutations
Dr Yohann Loriot and Dr Scott Tagawa
Latest in bladder cancer with FGFR 2 and 3 mutations ( Dr Yohann Loriot and Dr Scott Tagawa )
24 Sep 2020
PARP inhibitors and their evolving role for the treatment of prostate cancer
Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi
PARP inhibitors and their evolving role for the treatment of prostate cancer ( Dr Neal Shore, Dr Neeraj Agarwal, Dr Elena Castro and Dr Kim Chi )
24 Sep 2020
KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer
Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan
KEYNOTE-590: Pembrolizumab plus chemotherapy for advanced oesophageal cancer ( Prof Ken Kato - National Cancer Center Hospital, Chuo-ku, Japan )
24 Sep 2020
Disparities in access to oncology clinical trials across Europe
Prof Ana Carneiro - Lund University, Lund, Sweden
Disparities in access to oncology clinical trials across Europe ( Prof Ana Carneiro - Lund University, Lund, Sweden )
24 Sep 2020
ESMO 2020: Latest updates in prostate cancer
Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Johann De Bono and Prof Nick Jam...
ESMO 2020: Latest updates in prostate cancer ( Dr Eleni Efstathiou, Prof Boris Hadaschik, Prof Johann De Bono and Prof Nick James )
23 Sep 2020
ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients wit...
Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA
ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously treated mTNBC ( Dr Aditya Bardia - Massachusetts General Hospital, Boston, USA )
23 Sep 2020
ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer p...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
ALTA-1L: Brigatinib vs crizotinib for ALK  advanced non small cell lung cancer patients ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
23 Sep 2020
Breast cancer roundup from ESMO 2020
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
Breast cancer roundup from ESMO 2020 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
23 Sep 2020
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer
Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer ( Prof Leisha Emens - University of Pittsburgh, Pittsburgh, USA )
22 Sep 2020
ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer
Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan
ATTRACTION-4: Nivolumab plus chemotherapy for gastric or gastroesophageal cancer ( Prof Narikazu Boku - National Cancer Center Hospital, Tokyo, Japan )
22 Sep 2020
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or...
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004 ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
22 Sep 2020
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC aft...
Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection ( Dr Masahito Tsuboi - National Cancer Center Hospital, Tokyo, Japan )
22 Sep 2020
Latest updates to the ESMO bone health guidelines
Prof Robert Coleman - University of Sheffield, Sheffield, UK
Latest updates to the ESMO bone health guidelines ( Prof Robert Coleman - University of Sheffield, Sheffield, UK )
22 Sep 2020
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers
Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers ( Prof Markus Möhler - Universitätsmedizin Mainz, Mainz, Germany )
22 Sep 2020
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
22 Sep 2020
Estimate of the 2-year oncology workload generated by each new patient: A real-w...
Dr Silvio Ken Garattini - University of Udine, Udine, Italy
Estimate of the 2-year oncology workload generated by each new patient: A real-world study ( Dr Silvio Ken Garattini - University of Udine, Udine, Italy )
21 Sep 2020
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NS...
Dr Alex Spira and Dr Joshua Sabari
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC ( Dr Alex Spira and Dr Joshua Sabari )
21 Sep 2020
Impact of COVID-19 pandemic on cancer care: A global collaborative study
Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Ara...
Impact of COVID-19 pandemic on cancer care: A global collaborative study ( Prof Abdul-Rahman Jazieh - King Saud bin Abdulaziz University, Riyadh, Saudi Arabia )
21 Sep 2020
MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer
Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK
MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer ( Prof Stephen Johnston - Royal Marsden NHS Foundation Trust, London, UK )
21 Sep 2020
LungART: Radiotherapy after surgery for patients with non small cell lung cancer
Dr Cécile Le Péchoux - Gustave Roussy Cancer Campus, Villejuif, CEDEX, France
LungART: Radiotherapy after surgery for patients with non small cell lung cancer ( Dr Cécile Le Péchoux - Gustave Roussy Cancer Campus, Villejuif, CEDEX, France )
21 Sep 2020
Personalised molecularly matched therapies for carcinomas of unknown primary
Dr Jacob Adashek - University of South Florida, Tampa, USA
Personalised molecularly matched therapies for carcinomas of unknown primary ( Dr Jacob Adashek -  University of South Florida, Tampa, USA )
21 Sep 2020
Impact of COVID-19 on oncology professionals
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Impact of COVID-19 on oncology professionals ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
20 Sep 2020
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advan...
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
20 Sep 2020
Comparing real world evidence to phase III data on apalutamide for nmCRPC
Prof Heather Payne and Prof Stéphane Oudard
Comparing real world evidence to phase III data on apalutamide for nmCRPC ( Prof Heather Payne and Prof Stéphane Oudard )
19 Sep 2020
Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC
Dr Yungan Tao - Gustave Roussy Cancer Campus, Villejuif, France
Pembrolizumab vs cetuximab with radiotherapy in locally advanced HNSCC ( Dr Yungan Tao - Gustave Roussy Cancer Campus, Villejuif, France )
19 Sep 2020